Qingdao Haier Biomedical Co Ltd (688139) - Net Assets

Latest as of December 2025: CN¥4.62 Billion CNY ≈ $676.52 Million USD

Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) has net assets worth CN¥4.62 Billion CNY (≈ $676.52 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.79 Billion ≈ $847.48 Million USD) and total liabilities (CN¥1.17 Billion ≈ $170.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Qingdao Haier Biomedical Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.62 Billion
% of Total Assets	79.83%
Annual Growth Rate	22.9%
5-Year Change	27.05%
10-Year Change	N/A
Growth Volatility	41.49

Qingdao Haier Biomedical Co Ltd - Net Assets Trend (2016–2025)

This chart illustrates how Qingdao Haier Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Qingdao Haier Biomedical Co Ltd (688139) total assets for the complete picture of this company's asset base.

Annual Net Assets for Qingdao Haier Biomedical Co Ltd (2016–2025)

The table below shows the annual net assets of Qingdao Haier Biomedical Co Ltd from 2016 to 2025. For live valuation and market cap data, see how much is Qingdao Haier Biomedical Co Ltd worth.

Year	Net Assets	Change
2025-12-31	CN¥4.62 Billion ≈ $676.52 Million	+0.11%
2024-12-31	CN¥4.62 Billion ≈ $675.78 Million	+4.01%
2023-12-31	CN¥4.44 Billion ≈ $649.71 Million	+7.03%
2022-12-31	CN¥4.15 Billion ≈ $607.03 Million	+14.00%
2021-12-31	CN¥3.64 Billion ≈ $532.46 Million	+30.68%
2020-12-31	CN¥2.78 Billion ≈ $407.46 Million	+13.24%
2019-12-31	CN¥2.46 Billion ≈ $359.82 Million	+120.78%
2018-12-31	CN¥1.11 Billion ≈ $162.98 Million	+81.17%
2017-12-31	CN¥614.76 Million ≈ $89.96 Million	-14.95%
2016-12-31	CN¥722.81 Million ≈ $105.77 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Qingdao Haier Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 560.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥2.16 Billion	49.45%
Other Components	CN¥2.21 Billion	50.55%
Total Equity	CN¥4.38 Billion	100.00%

Qingdao Haier Biomedical Co Ltd Competitors by Market Cap

The table below lists competitors of Qingdao Haier Biomedical Co Ltd ranked by their market capitalization.

Company	Market Cap
Blackrock Municipal Target Term Closed Fund NYSE:BTT	$1.46 Billion
Med Life SA RO:M	$1.46 Billion
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A SHG:688190	$1.46 Billion
Focus Technology Co Ltd SHE:002315	$1.46 Billion
Ruentex Industries Ltd TW:2915	$1.46 Billion
Edifier Technology Co Ltd SHE:002351	$1.46 Billion
Longkou Union Chemical Co. Ltd. A SHE:301209	$1.46 Billion
Sansure Biotech Inc SHG:688289	$1.46 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Qingdao Haier Biomedical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,371,550,511 to 4,375,697,060, a change of 4,146,549 (0.1%).
Net income of 250,730,797 contributed positively to equity growth.
Dividend payments of 147,357,426 reduced retained earnings.
Other factors decreased equity by 99,226,821.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥250.73 Million	+5.73%
Dividends Paid	CN¥147.36 Million	-3.37%
Other Changes	CN¥-99.23 Million	-2.27%
Total Change	CN¥-	0.09%

Book Value vs Market Value Analysis

This analysis compares Qingdao Haier Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.29x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 12.21x to 2.29x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥2.59	CN¥31.56	x
2018-12-31	CN¥4.67	CN¥31.56	x
2019-12-31	CN¥7.74	CN¥31.56	x
2020-12-31	CN¥8.75	CN¥31.56	x
2021-12-31	CN¥11.43	CN¥31.56	x
2022-12-31	CN¥12.65	CN¥31.56	x
2023-12-31	CN¥13.31	CN¥31.56	x
2024-12-31	CN¥13.75	CN¥31.56	x
2025-12-31	CN¥13.76	CN¥31.56	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Qingdao Haier Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.73%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 10.77%
• Asset Turnover: 0.40x
• Equity Multiplier: 1.32x
Recent ROE (5.73%) is below the historical average (12.03%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	17.05%	25.56%	0.51x	1.31x	CN¥50.93 Million
2017	9.82%	9.72%	0.52x	1.94x	CN¥-1.08 Million
2018	10.27%	13.54%	0.38x	2.01x	CN¥3.00 Million
2019	7.42%	17.98%	0.33x	1.24x	CN¥-63.28 Million
2020	13.72%	27.17%	0.36x	1.42x	CN¥103.37 Million
2021	23.33%	39.75%	0.43x	1.35x	CN¥482.76 Million
2022	14.94%	20.98%	0.52x	1.37x	CN¥198.73 Million
2023	9.60%	17.80%	0.41x	1.31x	CN¥-17.00 Million
2024	8.39%	16.05%	0.39x	1.32x	CN¥-70.52 Million
2025	5.73%	10.77%	0.40x	1.32x	CN¥-186.84 Million

Industry Comparison

This section compares Qingdao Haier Biomedical Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $2,964,235,365
Average return on equity (ROE) among peers: 8.35%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Qingdao Haier Biomedical Co Ltd (688139)	CN¥4.62 Billion	17.05%	0.25x	$1.46 Billion
Shanghai Kehua Bio-Engineering Co Ltd (002022)	$1.03 Billion	22.10%	0.17x	$449.34 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)	$10.07 Billion	15.85%	0.50x	$4.35 Billion
Double Medical Technology Inc (002901)	$3.18 Billion	11.21%	0.39x	$2.60 Billion
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)	$615.62 Million	6.75%	0.04x	$571.62 Million
Lepu Medical Tech Beijing (300003)	$6.58 Billion	18.53%	1.30x	$3.90 Billion
INKON Life Technology Co Ltd (300143)	$1.48 Billion	0.71%	0.25x	$1.25 Billion
Edan Instruments Inc (300206)	$1.16 Billion	1.16%	0.17x	$1.28 Billion
Guangdong Biolight Meditech Co Ltd (300246)	$1.50 Billion	1.47%	0.62x	$696.90 Million
Beijing Leadman Biochemistry Co Ltd (300289)	$1.38 Billion	-3.70%	0.18x	$533.36 Million
Sinocare Inc (300298)	$2.65 Billion	9.46%	0.24x	$1.35 Billion

About Qingdao Haier Biomedical Co Ltd

SHG:688139 China Medical Devices

Market Cap

$1.46 Billion

CN¥9.99 Billion CNY

Market Cap Rank

#7530 Global

#1832 in China

Share Price

CN¥31.56

Change (1 day)

+0.51%

52-Week Range

CN¥29.83 - CN¥36.98

All Time High

CN¥147.76